Artery Therapeutics, Inc.
San Ramon, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 10 Duberstein Dr, San Ramon, CA 94583, USA
- Website
- arterytx.com
- Founded
- 2004
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| QPS Austria GMBH | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Scantox Neuro GMBH | Grambach, Steiermark | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Neucyte Inc. | Mountain View, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Artery Therapeutics, Inc., a self-certified small disadvantaged business based in San Ramon, California, operates as a prime recipient of federal biomedical research grants from the National Institute on Aging, conducting clinical-stage drug development and manufacturing activities in support of neurodegenerative disease therapeutics.
Artery is a for-profit corporate entity with no federal contracting footprint; its entire federal engagement to date consists of four Project Grants and Cooperative Agreements from the National Institute on Aging (CFDA 93.866 — Aging Research program) totaling $19.4 million obligated since 2019. The vendor's customer concentration is singular: all four awards derive from a single federal agency (NIH/National Institute on Aging, 100% of awards). Two of the four awards face ultimate completion within the next twenty-four months, representing potential recompete opportunity.
Artery's federal work centers on CS6253, a second-generation ABCA1 transporter agonist peptide candidate for hereditary APOE4-associated dementia and mild cognitive impairment. The most recent award — a $2.64 million Cooperative Agreement dated February 15, 2026, completing March 15, 2028 — funds two sequential clinical research studies: a subcutaneous pharmacokinetic feasibility study followed by a Phase 2A mechanism and proof-of-concept trial enrolling 48 APOE4 carriers with mild cognitive impairment to evaluate safety, tolerability, pharmacokinetics, and biomarker effects. A $2.45 million Project Grant dated September 10, 2025, completing August 31, 2026, covers manufacturing of approximately 2.3 kilograms of Good Manufacturing Practices-compliant drug substance for chronic toxicology studies in rodents and primates, executed in partnership with Ambiopharm, Inc., a Contract Development and Manufacturing Organization. An earlier $2.45 million Project Grant from September 2021 (completed December 2024) supported Phase 1 clinical trial material and chemistry, manufacturing, and controls activities. A fourth award from June 2019 funded foundational work leading to Investigational New Drug regulatory submission.
Quick answers
Is Artery Therapeutics, Inc. registered in SAM.gov?
Yes. Artery Therapeutics, Inc.'s SAM.gov registration is active through August 7, 2027.
What is Artery Therapeutics, Inc.'s CAGE code?
Artery Therapeutics, Inc.'s CAGE code is 62AP0, and its Unique Entity ID (UEI) is JHVKQN55S7Y5.
What is Artery Therapeutics, Inc.'s most recent federal award?
Artery Therapeutics, Inc.'s most recent federal grant award is CS6253 sequential subcutaneous pharmacokinetic study followed by phase 2A placebo-controlled trial with three fixed… (UG3AG098023), from National Institute on Aging (NIH), on February 15, 2026.
On GovTribe
See Artery Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors